Accelerated plasminogen activator inhibitor may prevent late XXXX after coronary stenting in @entity583 .

@entity1 @entity2289 @entity37706 @entity256 @entity583
BACKGROUND: Although acceleration of plasma @entity2289 ( @entity2289 ) level after emergent coronary angioplasty in @entity583 ( @entity583 ) has been documented, its pathophysiologic role is still unknown. HYPOTHESIS: This study was designed to elucidate the role of @entity2289 in the development of @entity256 after primary coronary stenting in @entity583 . METHODS: We selected for this study 66 @entity1 with @entity583 , who underwent primary coronary stenting for @entity37706 in an emergent situation. In all @entity1 , plasma @entity2289 level was measured at admission, and at 3 h, 24 h, 48 h, and 1 month after coronary stenting. RESULTS: At admission, the @entity2289 level was equivalent in 24 @entity1 who experienced @entity256 and in 42 @entity1 without @entity256 (28 +/- 4 vs. 29 +/- 4 ng/ml). In @entity1 with @entity256 , the levels did not change during the course after coronary stenting. In @entity1 without @entity256 , however, the level significantly increased at 3 h (48 +/- 9 ng/ml, p < 0.001), 24 h (42 +/- 9, p < 0.01), and 48 h (38 +/- 7, p < 0.05) after coronary stenting, and was restored to the level equivalent to that at admission (27 +/- 2 ng/ml) I month aftercoronary stenting. The @entity2289 level at 3 h after coronary stenting in @entity1 without @entity256 was significantly higher (p < 0.05) than the level (33 +/- 6 ng/ml) in @entity1 with @entity256 . Multiple logistic regression analysis indicated that the @entity2289 level 3 h after coronary stenting was an independent predictor of @entity256 (Wald chi2 = 3.826, p = 0.019, odds ratio 0.921, 95% confidence interval 0.866-0.961). CONCLUSION: Accelerated @entity2289 after coronary stenting in @entity1 with @entity583 may protect against the development of late @entity256 .
